Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1159]

ASCO GU 2024: Current best practice for mRCC

Prof Jens Bedke, Prof Thomas Powles, Prof Michael Staehler and Dr Wenxin Xu

ASCO GU 2024: Current best practice for mRCC ( Prof Jens Bedke, Prof Thomas Powles, Prof Michael Staehler and Dr Wenxin Xu )

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer

Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi...

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer ( Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi Kitamura )

Remote genetic testing has the potential to increase the uptake of testing in...

Dr Bruce Montgomery - University of Washington, Seattle, USA

Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems ( Dr Bruce Montgomery - University of Washington, Seattle, USA )

Stockholm3 offers a promising avenue for personalised risk-based prostate...

Dr Scott Eggener - The University of Chicago, Chicago, USA

Stockholm3 offers a promising avenue for personalised risk-based prostate cancer diagnosis ( Dr Scott Eggener - The University of Chicago, Chicago, USA )

Cabozantinib and atezolizumab show more efficacy compared to second NHT in...

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Baseline characteristics of patients with PSMA-PET–positive and –negative...

Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany

Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )

Enfortumab vedotin in combination with pembrolizumab is a potential new...

Dr Michiel Simon Van Der Heijden - Netherlands Cancer Institute, Amsterdam...

Enfortumab vedotin in combination with pembrolizumab is a potential new standard of care for 1L la/mUC ( Dr Michiel Simon Van Der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with...

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )

Personalised systemic treatment in advanced prostate cancer

Dr Karim Fizazi - Institute Gustave Roussy, Villejuif, France

Personalised systemic treatment in advanced prostate cancer ( Dr Karim Fizazi - Institute Gustave Roussy, Villejuif, France )

World Bladder Cancer Patient Coalition

Dr Lydia Makaroff - President, World Bladder Cancer Patient Coalition, Oxford...

World Bladder Cancer Patient Coalition ( Dr Lydia Makaroff - President, World Bladder Cancer Patient Coalition, Oxford, UK )

DNA methylation profile of prostate cancer aggressiveness in Ghana

Dr Alexandra Lindsey Djomkam Zune - West African Centre for Cell Biology of...

ESMO 2023: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2023: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

More from ecancer